Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270 · View on ClinicalTrials.gov ↗
Study Summary
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
Conditions Studied
Interventions
- BIOLOGICAL 4D-150 IVT
- BIOLOGICAL Aflibercept IVT
Study Locations (20)
Florida
- Rand Eye Institute — Deerfield Beach
- Retina Vitreous Consultants, LLP DBA Retina Group of Florida — Fort Lauderdale
- Vitreo Retinal Associates — Gainesville
- Florida Eye Associates — Melbourne
- Retinal Specialty Institute — Pensacola
- Retina Vitreous Associates of Florida — Tampa
California
- California Retina Consultants — Oxnard
- Retinal Consultants Medical Group — Sacramento
Arizona
- Barnet Delaney Perkins Eye Center — Phoenix
Colorado
- Colorado Retina Associates — Lakewood
Illinois
- University Retina and Macula Associates — Oak Forest
Indiana
- Retina Partners Midwest — Carmel
Maryland
- Cumberland Valley Retina Consultants — Hagerstown
Massachusetts
- Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2031-01 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05197270
The ClinicalTrials.gov registry entry for NCT05197270 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 4D Molecular Therapeutics, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Neovascular (Wet) Age-Related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions — of which 4D-150 IVT is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05197270 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05197270 about?
NCT05197270 is a clinical study titled "4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration". Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
What is the current status of trial NCT05197270?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 215 participants. The study started on 2021-12-09. Estimated completion is 2031-01.
What conditions does trial NCT05197270 study?
This clinical trial studies the following conditions: Neovascular (Wet) Age-Related Macular Degeneration. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05197270?
The interventions under investigation include: 4D-150 IVT (BIOLOGICAL), Aflibercept IVT (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05197270?
This trial is sponsored by 4D Molecular Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05197270 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.